Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Trial Profile

Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Fexapotide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Nymox Pharmaceutical Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jun 2016 Results published in Nymox Pharmaceutical media release.
    • 09 Feb 2016 Data from 18 months follow-up were published in a Nymox Pharmaceutical Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top